<DOC>
	<DOCNO>NCT01162551</DOCNO>
	<brief_summary>This phase 2 study look efficacy toxicity oral sirolimus combination oral methotrexate child refractory/relapsed ALL NHL . Secondary objective include characterize trough level produce administration oral sirolimus child refractory/relapsed ALL/NHL evaluate effect sirolimus intracellular target relate mTOR inhibition .</brief_summary>
	<brief_title>Trial Sirolimus Methotrexate Relapsed/Refractory Lymphoblastic Leukemia Lymphoma</brief_title>
	<detailed_description>At present child bone marrow combine bone marrow extramedullary relapse acute leukemia therapy 5-20 % long-term survival . Newer , target agent need identify integrated present cytotoxic chemotherapy regimen . Biologically targeted cancer agent , include signal transduction inhibitor like mammalian target rapamycin inhibitor ( MTIs ) , show great promise treat hematologic malignancy . A Phase 1 trial sirolimus ( MTI ) alone perform CHOP well tolerate DLTs evidence hit biologic target . While signal transduction inhibitor may efficacious single agent , likely targeted agent demonstrate great efficacy combination cytotoxic agents.Based upon pre-clinical humanize ALL mouse model propose study toxicity efficacy add sirolimus oral methotrexate relapse refractory patient . Patients &lt; 25 year age , time enrollment , second great relapse ALL NHL ( lymphoblastic lymphoma peripheral T-cell lymphoma ) eligible . ALL patient must least 10 % blast marrow NHL patient must radiologic physical evidence recurrence . Patients start daily oral sirolimus dose base upon goal trough level weekly oral methotrexate . All therapy do outpatient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients &lt; /= 25 year age , time enrollment , second great relapse ALL NHL . For ALL must histologic diagnosis &gt; 10 % blast marrow lymphoblastic lymphoma peripheral Tcell lymphoma must radiologic physical evidence recurrence . Lansky &gt; 50 % Karnofsky &gt; 50 % Negative Pregnancy Test Creatinine clearance radioisotope GFR &gt; 70ml/min/m2 OR serum creatinine base age /gender Pulse ox &gt; 94 % Total Bilirubin &lt; 1.5 x normal age ALT &lt; 5 x normal age Albumin &gt; 2g/dL Shortening fraction echo &gt; 28 % OR ejection fraction &gt; 50 % gate radionuclide study Patient know allergy sirolimus , FK506 mTOR inhibitor Patient take investigational antineoplastic drug Patient receive myelosuppressive chemo within 14 day &lt; 14 day elapse since local palliative XRT ( small port ) &lt; 28 day since prior craniospinal XRT 50 % radiation pelvis &lt; 28 day substantial BM radiation Hematopoietic growth factor within 7 day entry ( except erythropoietin . ) Patient take biologic agent within 14 day Post BMT/SCT evidence active GVHD , least &gt; 3 month must elapse Patient uncontrolled infection ( patient fungal disease , stable &lt; 14 day patient bacteremia without negative blood culture Existing nonhematologic toxicity &gt; grade 2 Use steroid hydroxyurea permit upto 14 day prior entry .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
</DOC>